Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095441 | 0.82 | ALDH1A1 (0.40) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL6571065 | 0.82 | CA1 (0.38) | LMNASMN1; SMN2HPGDTSHRKMT2A | |
| SCHEMBL8207291 | 0.78 | LMNA (0.43) | LMNASMN1; SMN2HPGDTSHRMEN1 | |
| SCHEMBL29023320 | 0.77 | LMNA (0.44) | LMNASMN1; SMN2HPGDTSHRMEN1 | |
| SCHEMBL11851873 | 0.76 | LMNA (0.42) | LMNASMN1; SMN2HPGDTSHRMEN1 | |
| SCHEMBL8983336 | 0.76 | TSHR (0.31) | LMNASMN1; SMN2TSHR | |
| SCHEMBL8975977 | 0.74 | LMNA (0.41) | LMNASMN1; SMN2HPGDTSHRMEN1 | |
| SCHEMBL11303942 | 0.73 | KMT2A (0.42) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL11310644 | 0.73 | TP53 (0.42) | LMNATSHRMEN1KMT2ATP53 | |
| SCHEMBL4593313 | 0.73 | TDP1 (0.47) | LMNAHPGDTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1845 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614214-B2 | Pyrazole amide compounds and uses thereof | SINOCHEM CORPORATION (CN) | 2013-12-24 | — | — | US | claimed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | claimed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | claimed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | claimed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | claimed |
| EP-0741741-B1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 2002-08-28 | — | — | EP | claimed |
| US-6066447-A | INCLUDING NUCLEOSIDE DIMERS WITH MODIFIED BACKBONES; FOR VIRICIDES AND ANTISENSE AGENTS | NOVARTIS CORPORATION (US) | 2000-05-23 | — | — | US | claimed |
| WO-1998000434-A1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 1998-01-08 | — | — | WO | claimed |
| EP-0538194-B1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA GEIGY AG (CH) | 1997-06-04 | — | — | EP | claimed |
| US-5332814-A | Process for the preparation of carbacyclic nucleosides, and intermediates | CIBA-GEIGY CORPORATION (US) | 1994-07-26 | — | — | US | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | claimed |
| EP-0542681-A1 | Process for the preparation of carbocyclic nucleosides and its intermediates | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | claimed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| EP-0354297-B1 | THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-08-05 | — | — | EP | claimed |
| US-4180571-A | Arylmalonamido-1-oxadethiacephalosporins | SHIONOGI & CO., LTD. (JP) | 1979-12-25 | — | — | US | claimed |
| US-4113495-A | 2,4,4-TRIMETHYL-2-(2,5-DIHYDROXYPHENYL)-6-HYDROXY-CHROMANS | FUJI PHOTO FILM CO., LTD. (JP) | 1978-09-12 | — | — | US | claimed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | claimed |
| US-3948877-A | POLYACRYLONITRILE, ACID MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | LMNA 2824/4885SMN1; SMN2 4012/4885HPGD 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.